Salvage chemotherapy with gemcitabine and oxaliplatin in heavily pretreated patients with metastatic breast cancer: A multicenter phase II study

Oncology

Volumn 70, Issue 4, 2006, Pages 273-279

  Kakolyris, S ^a   Kalbakis, K ^b   Potamianou, A ^c   Malamos, N ^d   Vamvakas, L ^b   Christophillakis, C ^e   Tselepatiotis, E ^f   Giassas, S ^b   Mavrousis, D ^b   Amarantidis, K ^a   Georgoulias, Vassilis ^b  

^a University General Hospital   (Greece)

^b UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^c Metaxas Anticancer Hospital   (Greece)

^d Department of Medical Oncology   (Greece)

^e 401 Military Hospital   (Greece)

^f IASO GENERAL HOSPITAL   (Greece)

Author keywords

Gemcitabine; Metastatic breast cancer; Oxalipatin

Indexed keywords

ANTHRACYCLINE; DEXAMETHASONE; DIAZEPAM; GEMCITABINE; ONDANSETRON; OXALIPLATIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; METASTASIS; MULTICENTER STUDY; MYELOPOIESIS; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SALVAGE THERAPY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33750539966     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096248     Document Type: Article

References (39)

1. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Sreafico C, Laffranchi A, Caraceni A, Martini C: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995;13:2688-2699.
2. Ravdin PM, Burris HA, Cook G, Eisenberg P, Kane M, Bierma WA, Mortimer J, Genevois E, Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13:2879-2885.
3. Conte PF, Baldini E, Gennari A, Michelotti A, Salvadori B, Tibaldi-Danesi R, Innocenti F, Gentile A, Del Anna R, Biadi O, Mariani M, Del Tacca M: Dose finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer. J Clin Oncol 1997;15:2510-2517.
4. Mavroudis D, Malamos N, Alexopoulos A, Kouroussis CH, Agelaki S, Sarra E, Potamianou A, Kosmas C, Rigatos G, Giannakakis T, Kalbakis K, Apostolaki F, Vlachonikolis J, Kakolyris S, Samonis G, Georgoulias V: Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: a multicenter phase II trial. Ann Oncol 1999;10:211-215.
5. Winer EP, Morrow M, Osborne CK, Harris JR: Malignant tumors of the breast; in De Vita VT, Hellman S, Rosenberg SA (eds): Cancer, Principles and Practice of Oncology, ed 6. Philadelphia, Lippincott and Wilkins, 2001, pp 1651-1726.
6. Carmichael J: The role of gemcitabine in the treatment of other solid tumors. Br J Cancer 1998;78(suppl 3):21-25.
7. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′, 2′-difluorodeoxy-cytidine on DNA synthesis. Cancer Res 1991;51:6110-6117.
8. Green M: Gemcitabine safety overview. Semin Oncol 1996;23(suppl 10):32-35.
9. Blackstein M, Vogel CL, Ambinder R, Cowan J, Iglesias J, Melemed A: Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002;62:2-8.
10. Spielmann M, Llombart-Cussac A, Kalla S, Espie M, Namer M, Ferrero JM, Dieras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001;60:303-307.
11. Gerson R, Senaro A, Villabos A, Ortiz C, Sánchez-Forgach E: Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors (abstract 572). Proc Am Soc Clin Oncol 2000;19.
12. Raymond E, Faivre S, Woynarowski JM, Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998;25(suppl 5):4-12.
13. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol 1996;52:1855-1865.
14. Woynarowski JM, Chapman WG, Napier C: Oxaliplatin effects on naked and intracellular DNA (abstract A2083). Proc Am Assoc Cancer Res 1997;38:311.
15. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998;25(suppl 5):13-22.
16. Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M: Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990;25:299-303.
17. Bleiberg H: Oxaliplatin (L-OHP): a new reality in colorectal cancer. Br J Cancer 1998; 7(suppl 4):1-3.
18. Garufi C, Nistico C, Brienza S, Vaccaro A, De Ottavio A, Zappala AR, Aschelter AM, Terzoli E: Single agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study. Ann Oncol 2001;12:179-182.
19. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999;44:117-123.
20. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small cell lung cancer and ovarian carcinoma. Ann Oncol 2002;13:1479-1489.
21. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore DF Jr, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA, Sargent DJ: Gemcitabine and oxaliplatin for patients with advanced or metastatic pancreatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 2002;13:553-557.
22. Mavroudis D, Pappas P, Kouroussis CH, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Vardakis N, Nikolaidou M, Samonis G, Marselos M, Georgoulias V: A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003;14:304-312.
23. Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 1981;47:207-214.
24. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm modulated rate compared with constant rate. J Natl Cancer Inst 1990;82:1046-1050.
25. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
26. Cox DR: The Analysis of Binary Data. London, Methuen, 1970.
27. Early Breast Cancer Trialists' Collaborative Group: Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930-942.
28. Stemmler J, Wohlrab B, Bose D, Losem C, Gutchow K, Rauthe G, Untch M, Vehling-Kaiser U, Brudler O, Heinemann V: Gemcitabine plus cisplatin in intensively pretreated metastatic breast cancer: a phase II trial (abstract 291). Proc Am Soc Clin Oncol 2003;22.
29. Chaudhry S, Abdel-Rahman H, Patil R, Mansour R, Mills G, Burton G: Prospective phase II study of weekly cisplatin-gemcitabine in refractory metastatic breast cancer (abstract 430). Proc Am Soc Clin Oncol 2000;19.
30. Doroshow J, Tetef M, Margolin K, Somlo G, Frankel P, Longmate J, Synold T, Gandara D, Lenz HJ, Albain K: Significant activity of gemcitabine and cisplatin in both heavily and minimally pretreated metastatic breast cancer patients: a California Cancer Consortium/Loyola University Chicago Trial (abstract 609). Proc Am Soc Clin Oncol 2000;19.
31. Catania C, Nole F, Balduzzi A, Franceschelli I, Marenghi C, Corsetto L, Sanna G, Noberasco C, Zampino MG, Goldhirsch A: Caring for heavily pretreated patients with metastatic breast cancer: carboplatin-gemcitabine combination is effective and well-tolerated (abstract 724). Proc Am Soc Clin Oncol 2004;23.
32. Cottu PH, Caruba T, Espie M, Madelaine-Chambrin I, Misset JL, Gross-Goupil M: Gemcitabine combined with oxaliplatin in advanced breast cancer: updated results of two parallel phase II studies (abstract 839). Proc Am Soc Clin Oncol 2005;24.
33. Misset JL, Chollet PH, Vennin PH, Laplaige P, Lucas V, Frobert JL, Castera D, Fabbro M, Langlois D, Dupont-Andre G, Otero G, Fandi A: Multicentric phase II-III trial of oxaliplatin versus cisplatin both in association with cyclophosphamide in the treatment of advanced ovarian cancer: toxicity, efficacy, results (abstract 1266). Proc Am Soc Clin Oncol 1997;16.
34. Bidoli P, Cortinovis D, Isa L, Fusi A, Pari F, Cullura D, Aitini E, Passa S, Formisano B, Bajetta E: Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin+gemcitabine, or oxaliplatin +gemcitabine or sequential carboplatin+ gemcitabine, docetaxel+gemcitabine in chemo-naïve patients with advanced/metastatic non-small cell lung cancer (abstract 7118). Proc Am Soc Clin Oncol 2005;24.
35. Broad A, Links M, Rosenthal MA, Mitchell P: Combination gemcitabine and oxaliplatin for advanced non-small cell lung cancer: an Australian multicenter randomized phase II sequencing trial (abstract 7244). Proc Am Soc Clin Oncol 2005;24.
36. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003;98:2664-2670.
37. Banner SE, Fetting JH, Brenner MH: A stopping rule for standard chemotherapy for metastatic breast cancer. Lessons from a survey of Maryland medical oncologists. Cancer Invest 1994;12:451-455.
38. Reichman BS, Seidman AD, Crown JP, Heelan R, Hakes TB, Lebwohl DE, Gilewski TA, Surbone A, Currie V, Hudis CA: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993;11:1943-1951.
39. Seidman AD, Reichman BS, Crown JP, Yao TJ, Currie V, Hakes TB, Hudis CA, Gilewski TA, Baselga J, Forsythe P: Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response. J Clin Oncol 1995;13:1152-1159.